Bispecific Antibody Takes a BiTE Out of B Cells in Rheumatoid Arthritis

Amgen’s B-cell-depleting therapy blinatumomab (Blincyto) showed signs of efficacy in rheumatoid arthritis, found an academic-sponsored pilot trial of the CD19xCD3 bispecific T-cell engager (BiTE) in six patients with the autoimmune disease.